Advertisement
Advanced searchCitation search
Skip main navigation
Close Drawer MenuOpen Drawer Menu
No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Jun 2004

BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE

    View All Author Information
    https://doi.org/10.1097/01.ju.0000123981.03084.06

    Abstract

    Purpose:

    Staging for prostate cancer often includes bone scanning and computerized tomography (CT). We systematically reviewed the published evidence for these tests.

    Materials and Methods:

    We searched MEDLINE for articles on these investigations in newly diagnosed cases of prostate cancer. Data were pooled based on prostate specific antigen (PSA), grade and tumor stage.

    Results:

    Among 23 studies examining the role of bone scan metastases were detected in 2.3%, 5.3% and 16.2% of patients with PSA levels less than 10, 10.1 to 19.9 and 20 to 49.9 ng/ml, respectively. Scanning detected metastases in 6.4% of men with organ confined cancer and 49.5% with locally advanced disease. Detection rates were 5.6% and 29.9% for Gleason scores 7 or less and 8 or greater, respectively.

    Among 25 studies CT documented lymphadenopathy in 0 and 1.1% of patients with PSA less than 20 and 20 ng/ml or greater, respectively. CT detection rate was 0.7% and 19.6% in patients with localized and locally advanced disease, respectively. Detection rates in patients with Gleason scores 7 or less and 8 or greater were 1.2% and 12.5%, respectively. These risks were typically much greater on pathological evaluation.

    Conclusions:

    Patients with low risk prostate cancer are unlikely to have metastatic disease documented by bone scan or CT. Therefore, these investigations should not be standard practice. However, patients with PSA 20 ng/ml or greater, locally advanced disease, or Gleason score 8 or greater are at higher risk for bone metastases and should be considered for bone scan. CT may be useful in patients with locally advanced disease or Gleason score 8 or greater but appears not to be of benefit in patients with increased PSA alone.

    References

    • 1 National Cancer Institute of Canada: Current incidence and mortality. In: Canadian Cancer Statistics 2001. Toronto, Canada, 2001 Google Scholar
    • 2 : Use of imaging tests for staging newly diagnosed prostate cancer: trends from CaPSURE database. J Urol1998; 160: 2102. Link, Google Scholar
    • 3 : The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol1982; 127: 928. Link, Google Scholar
    • 4 : Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology1976; 121: 431. Google Scholar
    • 5 : The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol1978; 50: 178. Google Scholar
    • 6 : Role of computed tomography in the evaluation and management of carcinoma of the prostate. Int J Radiat Oncol Biol Phys1982; 8: 283. Google Scholar
    • 7 : Prostate-specific antigen best practice policy-part II: prostate cancer staging and post-treatment follow-up. Urology2001; 57: 225. Google Scholar
    • 8 : Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology1992; 40: 346. Google Scholar
    • 9 : The value of computed tomography and ultrasound in assessment of pelvic lymph node metastases in patients with clinically locally confined carcinoma of the prostate. Scand J Urol Nephrol1988; 22: 7. Google Scholar
    • 10 : CAT scanning in staging of prostatic cancer. Urology1981; 18: 305. Google Scholar
    • 11 : The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol1987; 149: 315. Google Scholar
    • 12 : Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol1991; 145: 313. Link, Google Scholar
    • 13 : Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol1992; 70: 295. Google Scholar
    • 14 : The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA1993; 269: 57. Google Scholar
    • 15 : Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?. Am J Clin Oncol1994; 17: 432. Google Scholar
    • 16 : Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?. Br J Urol1995; 75: 778. Google Scholar
    • 17 : The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med1995; 22: 207. Google Scholar
    • 18 : Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest1995; 13: 31. Google Scholar
    • 19 : Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology1996; 47: 708. Google Scholar
    • 20 : Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int1996; 56: 169. Google Scholar
    • 21 : Which patients with prostatic carcinoma require a staging bone scan?. Br J Urol1997; 79: 611. Google Scholar
    • 22 : When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?. Br J Urol1997; 79: 770. Google Scholar
    • 23 : The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma. Int J Biol Markers1998; 13: 70. Google Scholar
    • 24 : Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?. Eur Urol1998; 33: 376. Google Scholar
    • 25 : Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J Radiol1998; 71: 1130. Google Scholar
    • 26 : Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand J Urol Nephrol1999; 33: 89. Google Scholar
    • 27 : The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol1999; 31: 481. Google Scholar
    • 28 : Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol1999; 35: 223. Google Scholar
    • 29 : The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med1999; 24: 579. Google Scholar
    • 30 : Serum bone alkaline phosphatase levels enhance the clinical utility of prostate-specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med1999; 26: 625. Google Scholar
    • 31 : Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys2000; 48: 1443. Google Scholar
    • 32 : Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected on bone scintigraphy in patients with newly diagnosed prostate carcinoma. Nucl Med Commun2000; 21: 617. Google Scholar
    • 33 : Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int2001; 88: 226. Google Scholar
    • 34 : Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer2002; 94: 964. Google Scholar
    • 35 : The value of computerized tomography in evaluation of pelvic lymph nodes. J Urol1981; 126: 63. Link, Google Scholar
    • 36 : Detecting lymphatic metastases from prostatic carcinoma: superiority of CT. AJR Am J Roentgenol1981; 137: 207. Google Scholar
    • 37 : Use of CT to reduce understaging in prostatic cancer: comparison with conventional staging techniques. AJR Am J Roentgenol1983; 141: 351. Google Scholar
    • 38 : Preoperative lymph node evaluation in prostatic cancer patients who are surgical candidates: the role of lymphangiography and computerized tomography scanning with directed fine needle aspiration. J Urol1985; 134: 84. Link, Google Scholar
    • 39 : The value of CT in detecting pelvic lymph node metastases in cases of bladder and prostate carcinoma. Scand J Urol Nephrol1986; 20: 261. Google Scholar
    • 40 : The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. J Urol1986; 136: 1231. Link, Google Scholar
    • 41 : Is preoperative computed tomography necessary in the management of patients treated for carcinoma of the prostate by 125iodine interstitial implantation and bilateral pelvic lymphadenectomy?. Am J Clin Oncol1987; 10: 50. Google Scholar
    • 42 : Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology1987; 162: 331. Google Scholar
    • 43 : CT evaluation of lymph node status at presentation of prostatic carcinoma. Br J Radiol1992; 65: 199. Google Scholar
    • 44 : Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol1992; 22: 281. Google Scholar
    • 45 : Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma. Eur Urol1993; 23: 348. Google Scholar
    • 46 : Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol1994; 151: 1310. Link, Google Scholar
    • 47 : Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology1994; 190: 315. Google Scholar
    • 48 : Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol1995; 154: 1392. Link, Google Scholar
    • 49 : Assessment of the utility of bone scan, CT scan and lymph node dissection in staging of patients with newly diagnosed prostate cancer. J Urol1995; 153: 493. abstract 495. Google Scholar
    • 50 : Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology1996; 48: 428. Google Scholar
    • 51 : Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Abdom Imaging1996; 21: 364. Google Scholar
    • 52 : Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys1996; 34: 33. Google Scholar
    • 53 : Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. Int J Radiat Oncol Biol Phys1996; 34: 543. Google Scholar
    • 54 : Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology1999; 54: 490. Google Scholar
    • 55 : Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology1999; 53: 367. Google Scholar
    • 56 : Diagnosis and staging of prostate carcinoma: what is really necessary?. Urol Int1999; 63: 57. Google Scholar
    • 57 : The role of staging CT scans in the treatment of prostate cancer: a retrospective audit. Clin Oncol (R Coll Radiol)2000; 12: 32. Google Scholar
    • 58 The Royal College of Radiologists' Clinical Oncology Information Network. British Association of Urological Surgeons. Guidelines on the management of prostate cancer. Clin Oncol (R Coll Radiol)1999; 11: S53. Google Scholar
    • 59 Prostate-specific antigen (PSA) best practice policy. American Urological Association. Oncology2000; 14: 267. Google Scholar
    • 60 : Cancer Management Guidelines for Prostate Cancer. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Genitourinary/Prostate/Staging/htm. Accessed 2003. Google Scholar
    • 61 : Guidelines on the Management of Prostate Cancer. http://www.nelh.nhs.uk/guidelinesbd/html/AFprostate.htm. Accessed 1999. Google Scholar

    From the Kuwait Cancer Control Center, Kuwait City, Kuwait (SA), and Department of Radiation Oncology, Hamilton Regional Cancer Centre and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    © 2004 by American Urological Association, Inc.
    Copyright © 2022 American Urological Association Education and Research, Inc.

    COPYRIGHT AND PERMISSIONS: The Journal of Urology® is the Official Journal of the American Urological Association Education and Research, Inc. and is published monthly by Wolters Kluwer Health Inc. The American Urological Association grants the Publisher full and exclusive publishing and distribution rights, worldwide, for both print and electronic media. Therefore no portions of the work(s) can be reproduced without written consent from the Publisher. Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the Get Content & Permissions link under the Article Tools box that appears on the right side of the page. For questions about the Rightslink service, e-mail [email protected] or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on authors permission requests are available at Journal Permission.

    For translation rights requests, contact Translations. For license to republish and distribute requests, contact Licensing. For special projects and reprints (U.S./Canada), contact Alan Moore or [email protected]. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at [email protected] or [email protected].

    PRIVACY POLICY: Access AUA’s Privacy Policy (Privacy Policy).

    Advertisement